NEW YORK (GenomeWeb) – The University of Texas MD Anderson Cancer Center and Guardant Health said today that they are entering a multi-year partnership that they hope will help accelerate the translation of Guardant's liquid biopsy technology into a standard-of-care tool for guiding the treatment of cancer patients.

Under the terms of the partnership, Guardant will help MD Anderson build multiple on-site liquid biopsy centers in which the center will develop new assays using Guardant's cell-free DNA-sequencing technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.